Cystatin C as an Early Marker of Cardiorenal Syndrome Type 1 in Patients Admitted with Acute Heart Failure

The development of acute renal dysfunction in patients with heart failure is known as cardiorenal syndrome (CRS) type 1. Cystatin C has emerged an alternative to serum creatinine which helps detect early deterioration the function, and turn help initiate necessary interventions management prevent kidney injury (AKI). This a prospective observational study was conducted Department Cardiology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. blood sample collected on day admission for cystatin creatinine, then subsequently followed days 2 7, identify Cardiorenal 1 developed 18 (35.3%) 51 admitted CCU. Most were men had median age 57.61±12.99 years. Patients who AKI higher level (1.58±0.191mg/L vs. 0.971±0.344 mg/L) also revealed that stage severity KDIGO correlated C. Serum proven good biomarker diagnosis